10.1 MNT for Liver, Gallbladder, and Pancreatic Disorders

The liver, gallbladder, and exocrine pancreas complete digestion and coordinate intermediary metabolism. Their diseases are high-yield because older restrictive diets have been replaced by evidence-based practice.

Hepatic Disorders

1. Liver Cirrhosis and End-Stage Liver Disease

Cirrhosis is characterized by diffuse fibrosis and the conversion of normal hepatic architecture into abnormal regenerative nodules, leading to portal hypertension, ascites, esophageal varices, and hepatic encephalopathy.

2. Evidence-Based MNT for Cirrhosis

• Energy Requirements: $30 - 35\text{ kcal/kg/day}$ (based on dry, edema-free body weight) to meet hypermetabolic demands and prevent tissue wasting.
• Protein Requirements: $1.2 - 1.5\text{ g/kg/day}$ dry weight.

• The Late-Evening Bedtime Snack: Cirrhotic patients experience accelerated starvation. Due to depleted hepatic glycogen stores and impaired gluconeogenesis, an overnight fast in a cirrhotic patient produces the metabolic equivalent of 72 hours of starvation in a healthy individual, triggering massive skeletal muscle proteolysis and fat oxidation. Providing a mandatory late-evening snack (200 to 300 kcal) containing complex carbohydrates and protein (e.g., cereal with milk, whole-wheat sandwich) suppresses overnight gluconeogenesis, preserves muscle mass, and improves nitrogen balance.
• Ascites Management: Enforce a dietary sodium restriction of $2{,}000\text{ mg/day}$ ($88\text{ mEq/day}$). Fluid restriction ($1.0 - 1.5\text{ L/day}$) is indicated only if severe dilutional hyponatremia is present (serum sodium $< 125\text{ mEq/L}$).
• Esophageal Varices: Prescribe a soft, low-roughage diet; avoid sharp, coarse, scratchy foods (e.g., hard crackers, raw chips) that can mechanically injure vulnerable varices and precipitate catastrophic hemorrhage.
• Hepatic Encephalopathy (HE): The primary treatment is medical (lactulose, which acidifies the colonic lumen to convert absorbable $NH_3$ into unabsorbable ammonium $NH_4^+$, and non-absorbable antibiotics like rifaximin). Maintain dietary protein at 1.2 to 1.5 g/kg/day. In the minority of patients with true, documented episodic protein intolerance, temporary substitution with vegetable and dairy protein sources (which are naturally higher in Branched-Chain Amino Acids [BCAA: leucine, isoleucine, valine] and lower in Aromatic Amino Acids [AAA: phenylalanine, tyrosine, tryptophan]) or supplementation with specialized BCAA formulas should be initiated.

Pancreatic and Biliary Disorders

1. Acute Pancreatitis

• Pathophysiology: Premature intrapancreatic activation of digestive zymogens (especially trypsinogen to trypsin), resulting in autodigestion of pancreatic parenchyma, severe inflammation, and vascular leakage. Gallstones and heavy alcohol abuse account for $> 80\%$ of cases.
• MNT Guidelines:
  • Mild Acute Pancreatitis: Traditional prolonged NPO is unnecessary. Initiate early oral feeding as soon as abdominal pain subsides and ileus resolves, using an easily digestible, low-fat solid or soft diet (low-fat diets reduce cholecystokinin release and postprandial pancreatic stimulation). There is no need to wait for serum lipase/amylase to normalize before feeding.
  • Severe Acute Pancreatitis: Early Enteral Nutrition (EN) initiated within 24 to 48 hours is significantly superior to Total Parenteral Nutrition (TPN), reducing multi-organ failure, systemic infections, and mortality by preserving gut mucosal barrier integrity and preventing bacterial translocation. Continuous feeding via a nasojejunal (NJ) tube placed past the ligament of Treitz minimizes pancreatic stimulation; however, standard nasogastric (NG) feeding is equally effective and well-tolerated in many clinical settings.

2. Chronic Pancreatitis

• Pathophysiology: Irreversible, progressive destruction of pancreatic exocrine and endocrine tissue with fibrous replacement. Loss of $> 90\%$ of exocrine secretory capacity produces pancreatic exocrine insufficiency (PEI), resulting in severe fat malabsorption, steatorrhea (fecal fat excretion $> 7\text{ g/24 hours}$), azotorrhea, and weight loss.
• MNT Guidelines:
  • Pancreatic Enzyme Replacement Therapy (PERT): Prescribe high-potency, enteric-coated microencapsulated lipase enzymes (e.g., pancrelipase) that must be taken with every meal and snack. Enteric coatings protect enzymes from gastric acid denaturation, dissolving at duodenal $\text{pH } > 5.5$.
  • Dietary Fat Intake: High-energy diet ($35\text{ kcal/kg/day}$), high-protein ($1.2 - 1.5\text{ g/kg/day}$). Clinical Practice Rule: Do NOT restrict dietary fat unless steatorrhea is unmanageable despite maximum PERT dosing. Unnecessary fat restriction severely exacerbates caloric deficits and protein-energy wasting.
  • Micronutrient Repletion: Fat-soluble vitamins (Vitamins A, D, E, and K) in water-miscible formulations; monitor Vitamin $B_{12}$ (pancreatic proteases are needed to cleave R-protein from $B_{12}$ in the duodenum to allow binding to intrinsic factor).
  • Strict Abstinence: Complete, lifelong cessation of all alcohol and tobacco use.

3. Cholecystitis and Cholelithiasis

• Pathophysiology: Gallstones (cholelithiasis) obstructing the cystic duct, causing chemical and bacterial inflammation of the gallbladder (cholecystitis).
• MNT Guidelines: During acute symptomatic episodes, prescribe a strict low-fat diet ($< 20 - 30\text{ g fat/day}$ or $< 25\%$ of total calories) to minimize cholecystokinin (CCK) secretion and suppress painful gallbladder contractions. Following cholecystectomy, bile flows continuously from the liver into the duodenum; patients should follow a low-fat diet initially, gradually advancing to normal dietary fat intake as the small intestine adapts.